FinancialBuzz.com’s latest The Buzz Show: Featuring Our Corporate News Recap on “Cytokinetics, Inc. Shares Jump Following Positive Phase 2 Clinical Trial Results”
Cytokinetics, Inc (NASDAQ: CYTK) surged over 45% in premarket trading after the company announced positive topline results from Cohorts 1 and 2 of REDWOOD-HCM, the Phase 2 clinical trial of CK-274.
The results of REDWOOD-HCM inform dose selection and support progression of CK-274 to a planned Phase 3 registrational clinical trial which is expected to start before the end of the year.
Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. As a leader in muscle biology and the mechanics of muscle performance, the company is developing small molecule drug candidates specifically engineered to impact muscle function and contractility.
For more information, please visit: Cytokinetics, Inc.
About The Buzz: A Financial Buzz Show on daily news, covering the most up to date financial information. The Buzz intends to provide factual and relevant information for its audience. The Buzz is 100% original content, created by Financial Buzz Media. Located on Wall Street in the heart of New York City’s financial district, FinancialBuzz.com is a credible source for the world’s latest trending financial and economic news. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content.